giovedì, 13 agosto 2026

Notizie AIOM – anno XVI n. 658

16 Gennaio 2018

Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo- controlled, multicenter study of Japanese patients (ONO- 7643-04)

Cachexia, described as weight loss (mainly in lean body mass ) and anorexia, is common in patients with advanced cancer. This study examined the efficacy and safety of anamorelin (ONO-7643), a novel selective ghrelin receptor agonist, in Japanese cancer patients with cachexia. ...
Leggi tutto

16 Gennaio 2018

Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin

Cisplatin-associated acute kidney injury (C-AKI) is common. We sought to develop and validate a predictive model for C-AKI after the first course of cisplatin. Clinical and demographic data were collected on patients who received cisplatin between 2000 and 2016 at two cancer ...
Leggi tutto

15 Gennaio 2018

FDA approves first treatment for breast cancer with a certain inherited genetic mutation

January 12, 2018 - The U.S. Food and Drug Administration today expanded the approved use of olaparib (tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic ...
Leggi tutto

15 Gennaio 2018

FDA Expands Afatinib’s Approval for Lung Cancer

January 14, 2018 - The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I. The approval for uncommon, ...
Leggi tutto

12 Gennaio 2018

10 gennaio 2018 – Pubblicazione schede di monitoraggio Registro Ruxolitinib (Mielofibrosi)

12 Gennaio 2018

FDA Grants Pembrolizumab/Lenvatinib Breakthrough Designation for RCC

January 9, 2018 - The FDA has granted the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib a breakthrough therapy designation for the treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC). The designation is ...
Leggi tutto

12 Gennaio 2018

12 gennaio 2018 – Report di valutazione dell’innovatività

12 Gennaio 2018

12 gennaio 2018 – Concorsi AIFA 2018

12 Gennaio 2018

PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market

January 12, 2018 - EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the suspension of the marketing authorisations for hydroxyethyl-starch (HES) solutions for infusion across the European Union. These products are used as plasma volume replacement ...
Leggi tutto

12 Gennaio 2018

Cost Effectiveness of Gene Expression Profile Testing in Community Practice

Gene expression profile (GEP) testing can support chemotherapy decision making for patients with early-stage, estrogen receptor-positive, human epidermal growth factor 2-negative breast cancers. This study evaluated the cost effectiveness of one GEP test, Onco type DX (Genomic ...
Leggi tutto